VEGFA and metastatic colorectal cancer: Several therapeutic agents targeting vascular endothelial growth factor (VEGF) have been developed, including bevacizumab, which was approved by the U.S. Food and Drug Administration (FDA) for metastatic colorectal cancer (mCRC) treatment [6].